Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SARS-CoV-2 virion is the complete, infectious unit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][5]. It is a spherical particle, typically 60–140 nanometers in diameter, consisting of a lipid envelope embedded with structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N)[1][2][5]. The envelope encloses the positive-sense single-stranded RNA genome, coated by nucleocapsid (N) protein[1][5][3]. The spike (S) protein, a glycoprotein, mediates attachment to the human ACE2 receptor and membrane fusion, allowing viral entry into host cells[2][6][8]. The M protein shapes the virion and aids in assembly; the E protein plays a role in envelope formation and viral morphogenesis[1][4][5]. The overall architecture supports viral infection, propagation, and pathogenesis[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Severe acute respiratory syndrome coronavirus 2 virion (SARS-CoV-2 virion).